Refining detection of drug-induced proarrhythmia: QT interval and TRIaD

Heart Rhythm

Volumn 2, Issue 7, 2005, Pages 758-772

  Shah, Rashmi R ^a,c   Hondeghem, Luc M ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NONE   (United Kingdom)

Author keywords

Dispersion of repolarization; Instability of repolarization; Proarrhythmia; QT prolongation; Reverse use dependency; Torsades de pointes; TRIaD; Triangulation of action potential

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CISAPRIDE; CONTRAST MEDIUM; DISOPYRAMIDE; DOLASETRON MESILATE; DROPERIDOL; FLUOXETINE; GRANISETRON; HALOPERIDOL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MIBEFRADIL; NICORANDIL; ONDANSETRON; PENTAMIDINE; PERHEXILINE; PHENYLEPHRINE; PHENYTOIN; PIPERANOMETOZINE; POTASSIUM CHANNEL HERG; PRIMIDONE; PROCAINAMIDE; QUINIDINE; QUINOLONE DERIVATIVE; RANOLAZINE; SOTALOL; TAMOXIFEN; TERFENADINE; TOLTERODINE; VERAPAMIL;

AFTERHYPERPOLARIZATION; ANGIOCARDIOGRAPHY; ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE MARKER; DRUG INDUCED DISEASE; DRUG POTENTIATION; HEART ELECTROPHYSIOLOGY; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IC 50; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER; QT INTERVAL; QT PROLONGATION; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SURVIVAL; T WAVE; TORSADE DES POINTES;

EID: 21344463329     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2005.03.023     Document Type: Article

References (186)

1. W. Frey Weitere erfahrungen mit chinidin bei absoluter herzunregelmäβigkeit Wien Med Wschr 55 1918 849-853
2. F. Dessertenne La tachycardie ventriculaire a deux foyers opposes variables Arch Mal Coeur 59 1966 263-272
3. R.R. Shah The significance of QT interval in drug development Br J Clin Pharmacol 54 2002 188-202
4. A. Keren D. Tzivoni D. Gavish J. Levi S. Gottlieb J. Benhorin S. Stern Etiology, warning signals and therapy of torsade de pointes: A study of 10 patients Circulation 64 1981 1167-1174
5. D.M. Roden Arrhythmogenic potential of class III antiarrhythmic agents comparison with class I agents In B.N. Singh editor Control of Cardiac Arrhythmias by Lengthening Repolarization 1988 Futura Publishing Mount Kisco, NY 559-577
6. P. Salle J.L. Rey P. Bernasconi J.C. Quiret M. Lombaert Torsades de pointe. Apropos of 60 cases (in French) Ann Cardiol Angeiol (Paris) 34 1985 381-388
7. D. Milon J.C. Daubert C. Saint-Marc J. Gouffault Torsade de pointes. Apropos of 54 cases (in French) Ann Fr Anesth Reanim 1 1982 513-520
8. M.C. Fung H. Hsiao-hui Wu K. Kwong K. Hornbuckle E. Muniz Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-1998 Pharmacoepidemiol Drug Saf 9 suppl 1 2000 S24-S25
9. M.E. Anderson S.M. Al-Khatib D.M. Roden R.M. Califf Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes. Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management Am Heart J 144 2002 769-781
10. J. Morganroth Relations of QTc prolongation on the electrocardiogram to torsades de pointes: Definitions and mechanisms Am J Cardiol 72 1993 10B-13B
11. H.G. Stratmann H.L. Kennedy Torsades de pointes associated with drugs and toxins: Recognition and management Am Heart J 113 1987 1470-1482
12. H.D. Gössinger P. Siostrzonek G. Schmoliner G. Grimm U. Jager H. Mosslacher Sotalol-induced torsade de pointes in a patient with pre-existing normal response to programmed ventricular stimulation Eur Heart J 8 1987 1351-1353
13. M.W. Burket T.D. Fraker P.N. Temesy-Armos Polymorphic ventricular tachycardia provoked by lidocaine Am J Cardiol 55 1985 592-593
14. C. Schmitt J. Brachmann W. Schöls T. Beyer W. Kübler Proarrhythmic effect of ajmaline in idiopathic ventricular tachycardia Dtsch Med Wochenschr 114 1989 99-102
15. H.R. Grogin M. Scheinman Evaluation and management of patients with polymorphic ventricular tachycardia Cardiol Clin 11 1993 39-54
16. D.S. Gambhir R. Salwan V.P. Sharma U.A. Kaul R. Arora Idiopathic polymorphic ventricular tachycardia with normal QT interval requiring implantable cardioverter-defibrillator device Indian Heart J 48 1996 292-294
17. P.T. Nguyen M.M. Scheinman J. Seger Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval Circulation 74 1986 340-349
18. B. Paltoo S. O'Donoghue M.S. Mousavi Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval Pacing Clin Electrophysiol 24 2001 895-897
19. L.M. Makarov T.A. Kuryleva S.N. Chuprova Shortening of PR interval, bradycardia and polymorphic ventricular tachycardia: clinico-electrocardiografical syndrome with high risk of sudden death in children Kardiologiia 43 2003 55-60
20. K.F. Kusano Y. Hata A. Yumoto T. Emori T. Sato T. Ohe Torsade de pointes with a normal QT interval associated with hypokalemia Jpn Circ J 65 2001 757-760
21. W.J. Brady D.J. DeBehnke D. Laundrie Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: A comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes Acad Emerg Med 6 1999 609-617
22. S.J. Eisenberg M.M. Scheinman N.K. Dullet W.e. J.C. Griffin M. Eldar M.R. Franz R. Gonzalez A.H. Kadish M.D. Lesh Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function Am J Cardiol 75 1995 687-692
23. T. Shiga M. Shoda N. Matsuda Y. Fuda N. Hagiwara S. Ohnishi A. Watanabe H. Kasanuki Electrophysiological characteristic of a patient exhibiting the short-coupled variant of torsade de pointes J Electrocardiol 34 2001 271-275
24. B. Strasberg W. Welch E. Palileo S. Swiryn R. Bauernfeind K.M. Rosen Familial inducible torsade de pointes with normal QT interval Eur Heart J 4 1983 383-390
25. W. Fehri S. Abdessalem Z. Smiri H. Mhenni N. Barakett N. Rahal H. Haouala Short coupled variant of torsade de pointes: Our experience and review of the literature (in French) Tunis Med 82 2004 867-874
26. J.L. Bauman R.A. Bauernfeind J.V. Hoff B. Strasberg S. Swiryn K.M. Rosen Torsade de pointes due to quinidine: Observations in 31 patients Am Heart J 107 1984 425-430
27. A.K. Bhandari M. Scheinman Torsade de pointes is the term necessary? In G.S. Brutus P. Schwartz editors Clinical Aspects of Ventricular Repolarization Part III 1989 Farrand Press London 305
28. L.M. Hondeghem Frequency dependence of class I and class III antiarrhythmic agents explaining their antiarrhythmic and proarrhythmic properties In M.R. Franz editor Monophasic Action Potentials 2000 Futura Publishing Mount Kisco, NY 381-394
29. L.M. Hondeghem P. Hoffmann Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability J Cardiovasc Pharmacol 41 2003 14-24
30. L.M. Hondeghem H.R. Lu K. van Rossem F. De Clerck Detection of proarrhythmia in the female rabbit heart: Blinded validation J Cardiovasc Electrophysiol 14 2003 287-294
31. L. Hondeghem L. Carlsson G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic Circulation 103 2001 2004-2013
32. I.G. Maia R. Sa P.A. Alves J.C. Ribeiro P.H. Fernandes O. Guarconi R. Bassan H.F. Dohmann Torsades de pointes: Analysis of 105 episodes (in Portuguese) Rev Port Cardiol 12 1993 163-168
33. G.N. Kay V.J. Plumb J.G. Arciniegras R.W. Henthorn A.L. Waldo Torsade de pointes: The long-short initiating sequence and other clinical features: observations in 32 patients J Am Coll Cardiol 2 1983 806-817
34. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013-1022
35. A. Leenhardt E. Glaser M. Burguera M. Nurnberg P. Maison-Blanche P. Coumel Short-coupled variant of torsade de pointes: A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias Circulation 89 1994 206-215
36. Y. Ruan L. Wang Short-coupled variant of torsade de pointes J Tongji Med Univ 21 2001 30-31
37. T. Takeuchi N. Sato Y. Kawamura F. Takahashi M. Sato K. Kikuchi N. Akasaka K. Go K. Fujimoto N. Hasebe A case of a short-coupled variant of torsades de pointes with electrical storm Pacing Clin Electrophysiol 26 Pt I 2003 632-636
38. A. Leenhardt V. Lucet I. Denjoy F. Grau D.D. Ngoc P. Coumel Catecholaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients Circulation 91 1995 1512-1519
39. N. Sumitomo K. Harada M. Nagashima T. Yasuda Y. Nakamura Y. Aragaki A. Saito K. Kurosaki K. Jouo M. Koujiro S. Konishi S. Matsuoka T. Oono S. Hayakawa M. Miura H. Ushinohama T. Shibata I. Niimura Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death Heart 89 2003 66-70
40. T. Yang D. Snyders D.M. Roden Drug block of IKr: Model systems and relevance to human arrhythmias J Cardiovasc Pharmacol 38 2001 737-744
41. A. Da Costa T. Chalvidan A. Belounas M. Messier M. Viallet H. Mansour D. Lamaison P. Djiane K. Isaaz Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: Role of QT dispersion and left ventricular function J Cardiovasc Electrophysiol 11 2000 990-997
42. P. Denes A. Gabster S.K. Huang Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring: Role of quinidine therapy Am J Cardiol 48 1981 9-16
43. D.K. Wysowski A. Corken H. Gallo-Torres L. Talarico E.M. Rodriguez Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions Am J Gastroenterol 96 2001 1698-1703
44. J.D. Minardo J.J. Heger W.M. Miles D.P. Zipes E.N. Prystowsky Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy N Engl J Med 319 1988 257-262
45. J.A. Arrowood D.F. Mullan R.A. Kline T.R. Engel P.R. Kowey Ventricular fibrillation during coronary angiography: The precatheterization QT interval J Electrocardiol 20 1987 255-259
46. R.F. Gilmour Jr M.L. Riccio E.H. Locati P. Maison-Blanche P. Coumel P.J. Schwartz Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation J Am Coll Cardiol 30 1997 209-217
47. R.R. Shah Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing Drug Saf 27 2004 145-172
48. M.B. Thomsen P.G. Volders M. Stengl R.L. Spatjens J.D. Beekman U. Bischoff M.A. Kall K. Frederiksen J. Matz M.A. Vos Electrophysiological safety of sertindole in dogs with normal and remodeled hearts J Pharmacol Exp Ther 307 2003 776-784
49. J. Ben-David D.P. Zipes Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs Circulation 82 1990 225-233
50. 1-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways Cardiovasc Res 53 2002 355-362
51. H. Huikuri Dispersion of repolarisation and the autonomic system: Can we predict torsade de pointes? Cardiovasc Drugs Ther 16 2002 93-99
52. N. Urao H. Shiraishi K. Ishibashi M. Hyogo M. Tsukamoto N. Keira S. Hirasaki T. Shirayama M. Nakagawa Idiopathic long QT syndrome with early afterdepolarizations induced by epinephrine Circ J 68 2004 587-591
53. 1-blockade in congenital long QT syndrome: Investigation by exercise stress test Jpn Circ J 65 2001 654-658
54. B.P. Grubb The use of oral labetalol in the treatment of arrhythmias associated with the long QT syndrome Chest 100 1991 1724-1725
55. H.J. Witchel V.K. Pabbathi G. Hofmann A.A. Paul J.C. Hancox Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents FEBS Lett 512 2002 59-66
56. X. Xu G.X. Yan Y. Wu T. Liu P.R. Kowey Electrophysiologic effects of SB-237376: A new antiarrhythmic compound with dual potassium and calcium channel blocking action J Cardiovasc Pharmacol 41 2003 414-421
57. I. Gussak P. Brugada J. Brugada R.S. Wright S.L. Kopecky B.R. Chaitman P. Bjerregaard Idiopathic short QT interval: A new clinical syndrome Cardiology 94 2000 99-102
58. F. Gaita C. Giustetto F. Bianchi C. Wolpert R. Schimpf R. Riccardi S. Grossi E. Richiardi M. Borggrefe Short QT syndrome: A familial cause of sudden death Circulation 108 2003 965-970
59. O.M. Makarov O.N. Chuprova O.I. Kiseleva QT interval shortening in families with history of sudden death at young age (in Russian) Kardiologiia 44 2004 51-56
60. R. Schimpf C. Wolpert F. Bianchi C. Giustetto F. Gaita U. Bauersfeld M. Borggrefe Congenital short QT syndrome and implantable cardioverter defibrillator treatment inherent risk for inappropriate shock delivery J Cardiovasc Electrophysiol 14 2003 1273-1277
61. C. Wolpert R. Schimpf C. Giustetto C. Antzelevitch J. Cordeiro R. Dumaine R. Brugada K. Hong U. Bauersfeld F. Gaita M. Borggrefe Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG J Cardiovasc Electrophysiol 16 2005 54-58
62. R. Brugada K. Hong R. Dumaine J. Cordeiro F. Gaita M. Borggrefe T.M. Menendez J. Brugada G.D. Pollevick C. Wolpert E. Burashnikov K. Matsuo Y.S. Wu A. Guerchicoff F. Bianchi C. Giustetto R. Schimpf P. Brugada C. Antzelevitch Sudden death associated with short-QT syndrome linked to mutations in HERG Circulation 109 2004 30-35
63. C. Bellocq A.C. van Ginneken C.R. Bezzina M. Alders D. Escande M.M. Mannens I. Baro A.A. Wilde Mutation in the KCNQ1 gene leading to the short QT-interval syndrome Circulation 109 2004 2394-2397
64. S.G. Priori S.V. Pandit I. Rivolta O. Berenfeld E. Ronchetti A. Dhamoon C. Napolitano J. Anumonwo M. Raffaele di Barletta S. Gudapakkam G. Bosi M. Stramba-Badiale J. Jalife A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene Circ Res 96 2005 800-807
65. D.L. DeSilvey A.J. Moss Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression Ann Intern Med 93 1980 53-54
66. J. Morganroth Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias Am J Cardiol 60 1987 1276-1281
67. ++ current Circ Res 64 1989 977-990
68. C. Antzelevitch W. Shimizu G.X. Yan S. Sicouri Cellular basis for QT dispersion J Electrocardiol 30 suppl 1998 168-175
69. B. Fermini A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development Nat Rev Drug Dis 2 2003 439-447
70. L. Belardinelli C. Antzelevitch M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol Sci 24 2003 619-625
71. C. Antzelevitch W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr Opin Cardiol 17 2002 43-51
72. C. Antzelevitch L. Belardinelli L. Wu H. Fraser A.C. Zygmunt A. Burashnikov J.M. Diego J.M. Fish J.M. Cordeiro R.J. Goodrow Jr F. Scornik G. Perez Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent J Cardiovasc Pharmacol Ther 9 suppl 1 2004 S65-S83
73. B.N. Singh N. Wadhani Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs J Cardiovasc Pharmacol Ther 9 suppl 1 2004 S85-S97
74. J.S. Mitcheson J. Chen M. Lin C. Culberson M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proc Natl Acad Sci U S A 97 2000 12329-12333
75. G.N. Tseng IKr: The hERG channel J Mol Cell Cardiol 33 2001 835-849
76. M. Chachin Y. Kurachi Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system Nippon Yakurigaku Zasshi 119 2002 345-351
77. L.M. Hondeghem TRIad Foundation for proarrhythmia (triangulation, reverse use dependence and instability) In D.J. Chadwick J. Goode editors The hERG Potassium Channel: Structure, function and long QT syndrome. Novartis Foundation Symposium No. 266 2005 Wiley Publications Chichester 235-244
78. L.M. Hondeghem K. Dujardin F. De Clerck Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia Cardiovasc Res 50 2001 345-353
79. E.M. Vaughan Williams Classification of antiarrhythmic agents In E.M. Vaughan Williams editor: Antiarrhythmic Drugs. Handbook of Experimental Pharmacology Series (No. 89) 1989 Springer-Verlag Berlin 45-67
80. J.-P. Valentin P. Hoffmann F. De Clerck T.G. Hammond L. Hondeghem Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs J Pharmacol Toxicol Methods 49 2004 171-181
81. L.H. Xie J.T. Xie Effects of tetrodoxin and verapamil on triggered activities induced by cesium chloride in cat heart in vivo (in Chinese) Zhongguo Yao Li Xue Bao 13 1992 38-41
82. E. Patterson B.J. Scherlag R. Lazzara Early afterdepolarizations produced by d,l-sotalol and clofilium J Cardiovasc Electrophysiol 8 1997 667-678
83. C.F. Starmer A.O. Grant T.J. Colatsky What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs Cardiovasc Res 57 2003 1062-1071
84. H.R. Lu E. Vlaminckx K. Van Ammel F. De Clerck Drug-induced long QT in isolated rabbit Purkinje fibers: Importance of action potential duration, triangulation and early afterdepolarizations Eur J Pharmacol 452 2002 183-192
85. A. Sugiyama Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models Nippon Yakurigaku Zasshi 121 2003 393-400
86. P. Milberg L. Eckardt H.J. Bruns J. Biertz S. Ramtin N. Reinsch D. Fleischer P. Kirchhof L. Fabritz G. Breithardt W. Haverkamp Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes J Pharmacol Exp Ther 303 2002 218-225
87. L. Eckardt G. Breithardt W. Haverkamp Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: Low torsadogenic potential despite QT prolongation J Pharmacol Exp Ther 300 2002 64-71
88. N.J. White S. Looareesuwan D.A. Warrell Quinine and quinidine: A comparison of EKG effects during the treatment of malaria J Cardiovasc Pharmacol 5 1983 173-175
89. T. Klingenheben G. Gronefeld Y.G. Li S.H. Hohnloser Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study J Am Coll Cardiol 38 2001 2013-2019
90. M. Chinushi Y. Aizawa H. Furushima H. Inuzuka K. Ojima A. Shibata Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome Jpn Heart J 36 1995 477-481
91. Y. Fujimoto H. Morita K.K. Fukushima T. Ohe Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome Heart 82 1999 8
92. Y. Fujimoto K.F. Kusano H. Morita K. Hong H. Yamanari T. Ohe Nicorandil attenuates both temporal and spatial repolarization alternans J Electrocardiol 33 2000 269-277
93. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome Circulation 102 2000 706-712
94. T. Sato Y. Hata M. Yamamoto H. Morita K. Mizuo H. Yamanari D. Saito T. Ohe Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome J Cardiovasc Electrophysiol 6 1995 279-282
95. ++ channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue J Pharmacol Exp Ther 292 2000 561-575
96. T. Meinertz Mibefradil - a drug which may enhance the propensity for the development of abnormal QT prolongation Eur Heart J 3 suppl K 2001 K89-K92
97. Committee for Proprietary Medicinal Products Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. (CPMP/986/96) 1997 European Medicines Agency (EMEA) London 17 December. Availabel at http://www.emea.eu.int/htms/human/swp/swpptc.htm. Accessed 10 February 2005
98. ICH Topic E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2004 Anon. Draft dated 10 June. Available at http://www.emea.eu.int/pdfs/human/ich/ 000204en.pdf. Accessed 10 February 2005
99. W. Haverkamp L. Eckardt G. Mönnig E. Schulze-Bahr H. Wedekind P. Kirchhof F. Haverkamp G. Breithardt Clinical aspects of ventricular arrhythmias associated with QT prolongation Eur Heart J 3 suppl K 2001 K81-K88
100. D.S. Echt P.R. Liebson L.B. Mitchell R.W. Peters D. Obias-Manno A.H. Barker D. Arensberg A. Baker L. Friedman H.L. Greene et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781-788
101. L.M. Hondeghem D.J. Snyders Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use-dependence Circulation 81 1990 686-690
102. + channels by vesnarinone Mol Pharmacol 60 2001 244-253
103. L. Wu J.C. Shryock Y. Song Y. Li C. Antzelevitch L. Belardinelli Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome J Pharmacol Exp Ther 310 2004 599-605
104. G.A. Gintant J.T. Limberis J.S. McDermott C.D. Wegner B.F. Cox The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis J Cardiovasc Pharmacol 37 2001 607-618
105. A.L. Waldo A.J. Camm H. deRuyter P.L. Friedman D.J. MacNeil J.F. Pauls B. Pitt C.M. Pratt P.J. Schwartz E.P. Veltri Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol Lancet 348 1996 7-12 (Erratum in Lancet 1996 348 416)
106. C.M. Pratt A.J. Camm W. Cooper P.L. Friedman D.J. MacNeil K.M. Moulton B. Pitt P.J. Schwartz E.P. Veltri A.L. Waldo Mortality in the Survival With ORal D-sotalol (SWORD) trial: Why did patients die? Am J Cardiol 81 1998 869-876
107. C. Torp-Pedersen M. Moller P.E. Bloch-Thomsen L. Kober E. Sandoe K. Egstrup E. Agner J. Carlsen J. Videbaek B. Marchant A.J. Camm Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group N Engl J Med 341 1999 857-865
108. A.J. Camm C.M. Pratt P.J. Schwartz H.R. Al-Khalidi M.J. Spyt M.J. Holroyde R. Karam E.H. Sonnenblick J.M. Brum AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification Circulation 109 2004 990-996
109. J.N. Weiss A. Garfinkel H.S. Karagueuzian Z. Qu P.S. Chen Chaos and the transition to ventricular fibrillation: A new approach to antiarrhythmic drug evaluation Circulation 99 1999 2819-2826
110. M.H. Lee Z. Qu G.A. Fishbein S.T. Lamp E.H. Chang T. Ohara O. Voroshilovsky J.R. Kil A.R. Hamzei N.C. Wang S.F. Lin J.N. Weiss A. Garfinkel H.S. Karagueuzian P.S. Chen Patterns of wave break during ventricular fibrillation in isolated swine right ventricle Am J Physiol Heart Circ Physiol 281 2001 H253-H265
111. M.B. Thomsen S.C. Verduyn M. Stengl J.D. Beekman G. de Pater J. van Opstal P.G. Volders M.A. Vos Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs Circulation 110 2004 2453-2459
112. A.A. Fossa M.J. DePasquale D.L. Raunig M.J. Avery D.J. Leishman The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment J Pharmacol Exp Ther 302 2002 828-833
113. W. Zareba A.J. Moss S. le Cessie W.J. Hall T wave alternans in idiopathic long QT syndrome J Am Coll Cardiol 23 1994 1541-1546
114. B. Houltz B. Darpo N. Edvardsson P. Blomstrom J. Brachmann H.J. Crijns S.M. Jensen E. Svernhage H. Vallin K. Swedberg Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study Pacing Clin Electrophysiol 21 1998 1044-1057
115. C.R. Kroll L.S. Gettes T wave alternans and torsades de pointes after the use of intravenous pentamidine J Cardiovasc Electrophysiol 13 2002 936-938
116. N. El-Sherif G. Turitto Torsade de pointes Curr Opin Cardiol 18 2003 6-13
117. P.P. Sharma P. Ott V.V. Hartz J.W. Mason F.I. Marcus Risk factors for tachycardia events caused by antiarrhythmic drugs: Experience from the ESVEM trial J Cardiovasc Pharmacol Ther 3 1998 269-274
118. W. Shimizu C. Antzelevitch Cellular and ionic basis for T-wave alternans under long-QT conditions Circulation 99 1999 1499-1507
119. A.A. Fossa T. Wisialowski E. Wolfgang E. Wang M. Avery D.L. Raunig B. Fermini Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig Eur J Pharmacol 486 2004 209-221
120. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome Circulation 102 2000 706-712
121. O. Watanabe T. Okumura H. Takeda W. Nakamura K. Segawa H. Ito N. Yoshimoto Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block Pacing Clin Electrophysiol 22 1999 686-688
122. Y. Fujimoto K.F. Kusano H. Morita K. Hong H. Yamanari T. Ohe Nicorandil attenuates both temporal and spatial repolarization alternans J Electrocardiol 33 2000 269-277
123. T. Sato Y. Hata M. Yamamoto H. Morita K. Mizuo H. Yamanari D. Saito T. Ohe Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome J Cardiovasc Electrophysiol 6 1995 279-282
124. K. Brockmeier I. Aslan T. Hilbel T. Eberle H.E. Ulmer R.L. Lux T-wave alternans in LQTS. repolarization-rate dynamics: From digital 12-lead Holter data J Electrocardiol 34 suppl 2001 93-96
125. M.A. Habbab N. el-Sherif TU alternans, long QTU, and torsade de pointes: clinical and experimental observations Pacing Clin Electrophysiol 15 1992 916-931
126. M.R. Franz Bridging the gap between basic and clinical electrophysiology: What can be learned from monophasic action potential recordings? J Cardiovasc Electrophysiol 5 1994 699-710
127. M.R. Franz M. Zabel Electrophysiological basis of QT dispersion measurements Prog Cardiovasc Dis 42 2000 311-324
128. G.X. Yan C. Antzelevitch Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome Circulation 98 1998 1928-1936
129. C. Antzelevitch W. Shimizu G.X. Yan S. icouri J. Weissenburger V.V. Nesterenko A. Burashnikov J. Di Diego J. Saffitz G.P. Thomas The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart J Cardiovasc Electrophysiol 10 1999 1124-1152
130. F.G. Akar G.X. Yan C. Antzelevitch D.S. Rosenbaum Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome Circulation 105 2002 1247-1253
131. J.M. Di Diego L. Belardinelli C. Antzelevitch Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation Circulation 108 2003 1027-1033
132. G.X. Yan Y. Wu T. Liu J. Wang R.A. Marinchak P.R. Kowey Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall Circulation 103 2001 2851-2856
133. Y.W. Qian Y.W. Qian R.J. Sung S.F. Lin R. Province W.T. Clusin Spatial heterogeneity of action potential alternans during global ischemia in the rabbit heart Am J Physiol Heart Circ Physiol 285 2003 H2722-H2733
134. B. Surawicz Torsades de pointes: Unanswered questions J Nippon Med Sch 69 2002 218-223
135. B.G. Katzung L.M. Hondeghem A.O. Grant Cardiac ventricular automaticity induced by current of injury Pflugers Arch 360 1975 193-197
136. M. Zaniboni A.E. Pollard L. Yang K.W. Spitzer Beat-to beat repolarization variability in ventricular myocytes and its suppression by electrical coupling Am J Physiol Heart Circ Physiol 278 2000 H677-H687
137. B.G. Katzung J.A. Morgenstern Effects of extracellular potassium on ventricular automaticity and evidence for a pacemaker current in mammalian ventricular myocardium Circ Res 40 1977 105-111
138. M. Viitasalo L. Oikarinen H. Swan H. Vaananen K. Glatter P.J. Laitinen K. Kontula H.V. Barron L. Toivonen M.M. Scheinman Ambulatory electrocardiographic evidence of transmural dispersion of repolarization in patients with long-QT syndrome type 1 and 2 Circulation 106 2002 2473-2478
139. Y. Tanabe M. Inagaki T. Kurita N. Nagaya A. Taguchi K. Suyama N. Aihara S. Kamakura K. Sunagawa K. Nakamura T. Ohe J.A. Towbin S.G. Priori W. Shimizu Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome J Am Coll Cardiol 37 2001 911-919
140. K. Takenaka T. Ai W. Shimizu A. Kobori T. Ninomiya H. Otani T. Kubota H. Takaki S. Kamakura M. Horie Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome Circulation 107 2003 838-844
141. A. Khositseth J. Nemec J. Hejlik W.K. Shen M.J. Ackerman Effect of phenylephrine provocation on dispersion of repolarization in congenital long QT syndrome Ann Noninvasive Electrocardiol 8 2003 208-214
142. W. Shimizu Y. Tanabe T. Aiba M. Inagaki T. Kurita K. Suyama N. Nagaya A. Taguchi N. Aihara K. Sunagawa K. Nakamura T. Ohe J.A. Towbin S.G. Priori S. Kamakura Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome J Am Coll Cardiol 39 2002 1984-1991
143. F. Extramiana C. Antzelevitch Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome Circulation 110 2004 3661-3666
144. M. Zabel M. Malik Practical use of T wave morphology assessment Card Electrophysiol Rev 6 2002 316-322
145. H. Yoshida A. Sugiyama Y. Satoh Y. Ishida M. Yoneyama K. Kugiyama K. Hashimoto Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model Circ J 66 2002 758-762
146. P.T. Sager P. Uppal C. Follmer M. Antimisiaris C. Pruitt B.N. Singh Frequency-dependent electrophysiologic effects of amiodarone in humans Circulation 88 1993 1063-1071
147. E.A. Sosunov E.P. Anyukhovsky M.R. Rosen Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts J Pharmacol Exp Ther 278 1996 906-912
148. D.G. Julian A.J. Camm G. Frangin M.J. Janse A. Munoz P.J. Schwartz P. Simon European Myocardial Infarct Amiodarone Trial Investigators Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT Lancet 349 1997 667-674
149. J.A. Cairns S.J. Connolly R. Roberts M. Gent Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations CAMIAT Lancet 349 1997 675-682
150. F. Boutitie J.P. Boissel S.J. Connolly A.J. Camm J.A. Cairns D.G. Julian M. Gent M.J. Janse P. Dorian G. Frangin The EMIAT and CAMIAT Investigators Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases Circulation 99 1999 2268-2275
151. Amiodarone Trials Meta-analysis Investigators Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials Lancet 350 1997 1417-1424
152. B.M. Massie S.G. Fisher M. Radford P.C. Deedwania B.N. Singh R.D. Fletcher S.N. Singh CHF-STAT Investigators Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure Circulation 93 1996 2128-2134
153. H.C. Doval D.R. Nul H.O. Grancelli S.V. Perrone G.R. Bortman R. Curiel Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Lancet 344 1994 493-498
154. B. Brendorp O. Pedersen C. Torp-Pedersen N. Sahebzadah L. Kober A benefit-risk assessment of class III antiarrhythmic agents Drug Saf 25 2002 847-865
155. M.F. Caron J. Kluger C.M. White Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias Ann Pharmacother 35 2001 1248-1254
156. T.A. Mattioni T.A. Zheutlin J.J. Sarmiento M. Parker M. Lesch R.F. Kehoe Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy Ann Intern Med 111 1989 574-580
157. R. Lazzara Amiodarone and torsade de pointes Ann Intern Med 111 1989 549-551
158. J. Merot F. Charpentier J.M. Poirier G. Coutris J. Weissenburger Effect of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol Cardiovasc Res 44 1999 303-314
159. S.H. Hohnloser T. Klingenheben B.N. Singh Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia Ann Intern Med 121 1994 529-535
160. P. Smetana E. Pueyo K. Hnatkova V. Batchvarov A.J. Camm M. Malik Effect of amiodarone on the descending limb of the T wave Am J Cardiol 92 2003 742-746
161. T. Aiba W. Shimizu M. Inagaki K. Satomi A. Taguchi T. Kurita K. Suyama N. Aihara K. Sunagawa S. Kamakura Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone Pacing Clin Electrophysiol 27 2004 901-909
162. S. Zhang Z. Zhou Q. Gong J.C. Makielski C.T. January Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ Res 84 1999 989-998
163. F.G. Cosio A. Goicolea M. Lopez Gil C. Kallmeyer J.L. Barroso Suppression of torsades de pointes with verapamil in patients with atrio-ventricular block Eur Heart J 12 1991 635-638
164. B.D. Walker S.M. Valenzuela C.B. Singleton H. Tie J.A. Bursill K.R. Wyse M.R. Qiu S.N. Breit T.J. Campbell Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate Br J Pharmacol 127 1999 243-251
165. J. Kang X.L. Chen H. Wang J. Ji W. Reynolds S. Lim J. Hendrix D. Rampe Cardiac ion channel effects of tolterodine J Pharmacol Exp Ther 308 2004 935-940
166. D. Thomas B. Gut G. Wendt-Nordahl J. Kiehn The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels J Pharmacol Exp Ther 300 2002 543-548
167. B.R. Danielsson K. Lansdell L. Patmore T. Tomson Phenytoin and phenobarbital inhibit human HERG potassium channels Epilepsy Res 55 2003 147-157
168. E. Ficker Y.A. Kuryshev A.T. Dennis C. Obejero-Paz L. Wang P. Hawryluk B.A. Wible A.M. Brown Mechanisms of arsenic-induced prolongation of cardiac repolarization Mol Pharmacol 66 2004 33-44
169. Y.A. Kuryshev E. Ficker L. Wang P. Hawryluk A.T. Dennis B.A. Wible A.M. Brown J. Kang X.L. Chen K. Sawamura W. Reynolds D. Rampe Pentamidine-induced long QT syndrome and block of hERG trafficking J Pharmacol Exp Ther 312 2005 316-323
170. + channel HERG Mol Pharmacol 59 2001 122-126
171. Y.A. Kuryshev A.M. Brown L. Wang C.R. Benedict D. Rampe Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels J Pharmacol Exp Ther 295 2000 614-620
172. X.K. Liu A. Katchman S.N. Ebert R.L. Woosley The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes J Pharmacol Exp Ther 287 1998 877-883
173. ++ current in rabbit ventricular myocytes Eur J Pharmacol 376 1999 189-201
174. M. Packer M.B. Fowler E.B. Roecker A.J. Coats H.A. Katus H. Krum P. Mohacsi J.L. Rouleau M. Tendera C. Staiger T.L. Holcslaw I. Amann-Zalan D.L. DeMets Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194-2199
175. S. Sicouri D. Antzelevitch C. Heilmann C. Antzelevitch Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome J Cardiovasc Electrophysiol 8 1997 1280-1290
176. J. Nemec J.B. Hejlik W.K. Shen M.J. Ackerman Catecholamine-induced T-wave lability in congenital long QT syndrome: A novel phenomenon associated with syncope and cardiac arrest Mayo Clin Proc 78 2003 40-50
177. T. Noda W. Shimizu K. Satomi K. Suyama T. Kurita N. Aihara S. Kamakura Classification and mechanism of torsade de pointes initiation in patients with congenital long QT syndrome Eur Heart J 25 2004 2149-2154
178. A.J. Moss W. Zareba J. Benhorin E.H. Locati W.J. Hall J.L. Robinson P.J. Schwartz J.A. Towbin G.M. Vincent M.H. Lehmann ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome Circulation 92 1995 2929-2934
179. A.J. Moss T-wave patterns associated with the hereditary long QT syndrome Card Electrophysiol Rev 6 2002 311-315
180. J.S. Perkiomaki W. Zareba A. Nomura M. Andrews E.S. Kaufman A.J. Moss Repolarization dynamics in patients with long QT syndrome J Cardiovasc Electrophysiol 13 2002 651-656
181. J.M. Lupoglazoff I. Denjoy M. Berthet N. Neyroud L. Demay P. Richard B. Hainque G. Vaksmann D. Klug A. Leenhardt G. Maillard P. Coumel P. Guicheney Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations Circulation 103 2001 1095-1101
182. A. Kandori W. Shimizu M. Yokokawa S. Kamakura K. Miyatake M. Murakami T. Miyashita K. Ogata K. Tsukada Reconstruction of action potential of repolarization in patients with congenital long-QT syndrome Phys Med Biol 49 2004 2103-2115
183. L. Burattini W. Zareba E.J. Rashba J.P. Couderc J. Konecki A.J. Moss ECG features of microvolt T-wave alternans in coronary artery disease and long QT syndrome patients J Electrocardiol 31 suppl 1998 114-120
184. J. Nemec M.J. Ackerman D.J. Tester J. Hejlik W.K. Shen Catecholamine-provoked microvoltage T wave alternans in genotyped long QT syndrome Pacing Clin Electrophysiol 26 2003 1660-1667
185. W.S. Redfern L. Carlsson A.S. Davis W.G. Lynch I. MacKenzie S. Palethorpe P.K. Siegl I. Strang A.T. Sullivan R. Wallis A.J. Camm T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development Cardiovasc Res 58 2003 32-45
186. R.L. Martin J.S. McDermott H.J. Salmen J. Palmatier B.F. Cox G.A. Gintant The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block J Cardiovasc Pharmacol 43 2004 369-379